FINAL RESULTS FROM THE AXIG TRIAL: A RANDOMIZED PHASE II CLINICAL TRIAL INVESTIGATING AXITINIB ALONE OR IN COMBINATION WITH CCNU IN PATIENTS WITH RECURRENT GLIOBLASTOMA

被引：0
|
作者：
Duerinck, Johnny [1 ]
Du Four, Stephanie [1 ]
Bouttens, Frank [2 ]
Verschaeve, Vincent [3 ]
Chaskis, Cristo [9 ]
Andre, Chantal [4 ]
Van Fraeyenhove, Frank [5 ]
D'haene, Nicky [6 ]
Salmon, Isabelle [7 ]
Neyns, Bart [8 ]
机构：
[1] Uz Brussel, Dept Neurosurg, Brussels, Belgium
[2] Az Sint Lucas, Dept Radiotherapy, Ghent, Belgium
[3] GhDC, Dept Med Oncol, Charleroi, Belgium
[4] CHU ULG, Dept Med Oncol, Liege, Belgium
[5] ZNA Middelheim, Dept Med Oncol, Antwerp, Belgium
[6] Erasmus Hosp, Dept Pathol, Brussels, Belgium
[7] Erasmus Hosp, Dept Pathol, Brussels, Belgium
[8] Uz Brussel, Dept Med Oncol, Brussels, Belgium
[9] CHU, Dept Neurosurg, Charleroi, Charleroi, Belgium
来源：
NEURO-ONCOLOGY | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ACTR-29
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [1] AXITINIB FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA, FINAL RESULTS FROM A RANDOMIZED PHASE II CLINICAL TRIAL
    Duerinck, J.
    Du Four, S.
    Bouttens, F.
    Verschaeve, V.
    Andre, C.
    Van Fraeyenhove, F.
    Chaskis, C.
    D'haene, N.
    Salmon, I.
    Neyns, B.
    NEURO-ONCOLOGY, 2016, 18 : 41 - 42
  • [2] Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma
    J. Duerinck
    S. Du Four
    F. Bouttens
    C. Andre
    V. Verschaeve
    F. Van Fraeyenhove
    C. Chaskis
    N. D’Haene
    M. Le Mercier
    A. Rogiers
    A. Michotte
    I. Salmon
    B. Neyns
    Journal of Neuro-Oncology, 2018, 136 : 115 - 125
  • [3] Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma
    Duerinck, J.
    Du Four, S.
    Bouttens, F.
    Andre, C.
    Verschaeve, V.
    Van Fraeyenhove, F.
    Chaskis, C.
    D'Haene, N.
    Le Mercier, M.
    Rogiers, A.
    Michotte, A.
    Salmon, I.
    Neyns, B.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 136 (01) : 115 - 125
  • [4] Axitinib for the treatment of recurrent glioblastoma - early results from a randomized phase II trial
    Duerinck, J.
    Du Four, S.
    Van Binst, A.
    Everaert, H.
    D'haens, J.
    Neyns, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S791 - S791
  • [5] EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
    Franceschi, Enrico
    Stupp, Roger
    van den Bent, Martin J.
    van Herpen, Carla
    Donadey, Florence Laigle
    Gorlia, Thierry
    Hegi, Monika
    Lhermitte, Benoit
    Strauss, Lewis C.
    Allgeier, Anouk
    Lacombe, Denis
    Brandes, Alba A.
    NEURO-ONCOLOGY, 2012, 14 (12) : 1503 - 1510
  • [6] Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
    Bota, Daniela A.
    Mason, Warren
    Kesari, Santosh
    Magge, Rajiv
    Winograd, Benjamin
    Elias, Ileana
    Reich, Steven D.
    Levin, Nancy
    Trikha, Mohit
    Desjardins, Annick
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [7] GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
    Neyns, Bart
    Ben Salama, Laila
    Awada, Gil
    De Cremer, Jennifer
    Schwarze, Julia Katharina
    Seynaeve, Laura
    Du Four, Stephanie
    Fischbuch, Lydia
    Vanbinst, Anne-Marie
    Everaert, Hendrik
    Michotte, Alex
    Rogiers, Anne
    Theuns, Peter
    Duerinck, Johnny
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
    Fallah, Jaleh
    Chaudhary, Rekha T.
    Rogers, Lisa R.
    Wei, Wei
    Brewer, Cathy J.
    Peereboom, David M.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
    Duerinck, Johnny
    Du Four, Stephanie
    Bouttens, Frank
    Verschaeve, Vincent
    Andre, Chantal
    Van Fraeyenhove, Frank
    Chaskis, Cristo
    D'Haene, Nicky
    Le Mercier, Marie
    Salmon, Isabelle
    Neyns, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
    Bota, D. A.
    Eroglu, Z.
    Reardon, D. A.
    Fu, B. D.
    Norfleet, J.
    Desjardins, A.
    Linskey, M. E.
    Peters, K.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345